October 21st 2024
Research shows that after 60 months of treatment, 38% of patients achieved complete remission.
September 10th 2024
Vitiligo Repigmentation Improvements More Noticeable in Patient-Reported Outcome Measures
August 23rd 2022Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
Read More
FDA Accepts Dupixent Application for Treating Skin Lesions
June 1st 2022If approved, Dupixent would be the first and only medicine in the United States specifically indicated to treat prurigo nodularis, or persistent itch with thick skin lesions. The PDUFA target action date for the FDA decision is Sept. 30, 2022.
Read More
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
Read More
Actavis to buy Warner Chilcott for $8.5 billion in stock transaction
May 20th 2013Actavis Inc. announced May 20 its plans to acquire Warner Chilcott in a stock transaction deal, which is worth approximately $8.5 billion. The merger is expected to create a global specialty pharmaceutical company serving the women’s health, gastroenterology, urology, and dermatology therapeutic sectors, according to a joint company release.
Read More
FDA approves Sylatron for injection for adjuvant treatment of melanoma
April 12th 2011FDA has approved peginterferon alfa-2b (Sylatron, Merck) for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.
Read More